The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305613 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Franke A Quee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Donor Medicine Research, Sanquin Research, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Viral, SARS-CoV-2, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Sanquin Bloedvoorziening, Ministerie van Volksgezondheid, Welzijn en Sport.
Abstract (Originalsprache)
Introduction
Serological surveillance is useful for assessing SARS-CoV-2 immunity in populations. To effectively study the presence and persistence of antibodies, it is necessary to distinguish between persons with past infection, and persons who only received vaccination. Knowledge of the duration of antibody persistence is essential for correct interpretation of surveillance results.
Methods
Starting in April 2020, waning of SARS-CoV-2 antibodies was studied in a longitudinal cohort study of 495 SARS-CoV-2 antibody-positive Dutch blood donors, not pre-selected by PCR testing or disease severity. Additionally, in May 2021, a sample of donors representative for the Dutch population was tested for antibodies against the SARS-CoV-2 spike (S) protein, using the Wantai Ab ELISA and the Elecsys® Anti-SARS-CoV-2 S assay; and for antibodies against the nucleocapsid protein, which indicate past infection, using the Elecsys® Anti-SARS-CoV-2 assay.
Results
The anti-S response in donors that were infected in April or May 2020 remained positive in 100% of donors in the Elecsys® Anti-SARS-CoV-2 S assay one year after infection, after which follow up of waning was no longer possible because of large scale vaccination. The anti-nucleocapsid response results were still positive in approximately 80% of donors two years after infection. In May 2021, 51% of the donors showed anti-S reactivity and 16.8% tested positive for anti-nucleocapsid antibodies.
Conclusion
Infection with SARS-CoV-2 resulted in spike and nucleocapsid antibody levels still detectable in the majority of donors 1–2 years after infection. In May 2021, 51% of donors were vaccinated and 16.8% had had an infection. Thus, both Elecsys® SARS-CoV-2 antibody assays can be used to reliably assess the vaccination and infection status of individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Donor Medicine Research, Sanquin Research, Amsterdam, The Netherlands.
- Department of Virology, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
- Department of Medical Affairs, Sanquin Corporate Staff, Sanquin Research, Amsterdam, The Netherlands.
- Department of Clinical Virology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
ORCID-Profile: Franke A Quee
Förderung
- Stichting Sanquin Bloedvoorziening
- Ministerie van Volksgezondheid, Welzijn en Sport
Zitieren
APA
Quee, F. A., Hogema, B. M., Molier, M., Slot, E., van den Hurk, K., & Zaaijer, H. L. (2024). The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance. PLOS ONE. https://doi.org/10.1371/journal.pone.0305613
Vancouver
Quee FA, Hogema BM, Molier M, Slot E, van den Hurk K, Zaaijer HL. The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance. PLOS ONE. 2024. doi:10.1371/journal.pone.0305613
BibTeX
@article{Quee2024,
author = {Quee, Franke A and Hogema, Boris M and Molier, Michel and Slot, Ed and van den Hurk, Katja and Zaaijer, Hans L},
title = {The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305613}
}
EUVIMED